EktaH has advanced its lead candidate, NKS-3, into Phase 2 clinical development for obesity, with the first patient enrolled in the exploratory Phase IIa SERENITY-1 study in Tunisia. The company has also secured EUR 2.4 million in non-dilutive funding from Bpifrance to support further clinical development, including preparations for a larger Phase 2 study in France.
The SERENITY-1 study (NCT07882654) is a randomised, single-blind, placebo-controlled trial being conducted at the Institut National de Nutrition de Tunis. It plans to enrol approximately 31 adults with obesity, who will receive either NKS-3 or placebo for 90 days. The treatment is administered at 7.5 mg twice daily.
The primary endpoint is the percentage change in body weight from baseline to Day 90. Secondary assessments will evaluate safety, tolerability, sensitivity to linoleic acid and changes in body composition, including fat and skeletal muscle mass. Topline results are expected in the first quarter of 2027.
The Bpifrance funding will support a 90-day toxicology study, Chemistry, Manufacturing and Controls (CMC) activities, and Phase 2 clinical development. The funding package comprises grant funding and reimbursable advances, with disbursements linked to development and regulatory milestones.
EktaH is also planning a larger Phase 2 programme in France to evaluate a new formulation of NKS-3 as a standalone weight-loss treatment and as a potential maintenance therapy following GLP-1 treatment discontinuation. One planned study is expected to enrol approximately 100 adults with obesity and compare two dosing regimens with placebo. The proposed programme will include 12 weeks of treatment followed by a 12-week off-treatment follow-up, subject to regulatory and ethics approvals. The company aims to submit its Clinical Trial Application in early 2027 and enrol the first patient in the second half of the year.
EktaH is completing its Phase 1 study of NKS-3 and NKS-5, two modified linoleic acids, involving 120 adults with obesity. Preliminary data from 22 participants treated with NKS-3 for 30 days showed no serious adverse events considered related to the candidate had been reported at the time of the announcement. The company expects to complete the database review by the end of November 2026 and release final results in Q1 2027.
NKS-3 is an oral modified fatty acid molecule designed to activate the fat taste receptors CD36 and GPR120, which are involved in the body's natural satiety signalling. The candidate aims to stimulate the release of satiety hormones, including GLP-1, cholecystokinin (CCK) and peptide YY (PYY), without administering these hormones directly.
In preclinical studies involving obese mice, NKS-3 was associated with approximately 50 percent less weight regain following semaglutide discontinuation compared with control animals, while preserving lean body mass. The candidate has also demonstrated anti-inflammatory activity in experimental models. These findings are preliminary and require further evaluation in clinical studies.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy